Targeting the WNT signaling pathway in cancer therapeutics

Oncologist

Volumn 20, Issue 10, 2015, Pages 1189-1198

  Tai, David ^a   Wells, Keith ^b   Arcaroli, John ^b   Vanderbilt, Chad ^b   Aisner, Dara L ^b   Messersmith, Wells A ^b   Lieu, Christopher H ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Drug development; Frizzled; Signal transduction; WNT; Catenin

Indexed keywords

7, 8 DIHYDRO 2 [4 (TRIFLUOROMETHYL) PHENYL] 5H THIOPYRANO [4, 3 D] PYRIMIDIN 4 OL; ANTINEOPLASTIC AGENT; AXIN; BETA CATENIN; BHQ880; CARBOXY TERMINAL TELOPEPTIDE; CWP232291; DICKKOPF 1 PROTEIN; DKN 01; G007 LK; G244 LM; IPAFRICEPT; IWR 1; JW55; LGK974; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; PRI 724; TANKYRASE INHIBITOR; UNCLASSIFIED DRUG; VANTICTUMAB; CTNNB1 PROTEIN, HUMAN; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ABDOMINAL PAIN; ANOREXIA; ARTHRALGIA; ARTICLE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; FATIGUE; FEVER; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MULTIPLE MYELOMA; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; SOLID TUMOR; THROMBOCYTOPENIA; WNT SIGNALING PATHWAY; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CLINICAL TRIALS AS TOPIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84943244867     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0057     Document Type: Article

References (78)

1. Clevers H.Wnt/b-catenin signaling in development and disease. Cell 2006;127:469-480.
2. De A. Wnt/Ca21 signaling pathway: A brief overview. Acta Biochim Biophys Sin (Shanghai) 2011;43:745-756.
3. Papkoff J, Brown AM, Varmus HE. The int-1 proto-oncogene products are glycoproteins that appear to enter the secretory pathway.Mol Cell Biol 1987;7:3978-3984.
4. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009;10: 468-477.
5. Kohn AD, Moon RT.Wnt and calcium signaling: Beta-catenin-independent pathways. Cell Calcium 2005;38:439-446.
6. Behrens J, Jerchow B-A, Würtele M et al. Functional interaction of an axin homolog, conductin, with b-catenin, APC, and GSK3b. Science 1998;280:596-599.
7. Hart MJ, de los Santos R, Albert IN et al. Downregulation of b-catenin by human Axin and its association with the APC tumor suppressor, b-catenin and GSK3 b. Curr Biol 1998;8:573- 581.
8. Bao R, Christova T, Song S et al. Inhibition of tankyrases induces Axin stabilizationandblocksWnt signalling in breast cancer cells. PLoS One 2012;7: e48670.
9. Jones SE, Jomary C. Secreted Frizzled-related proteins: Searching for relationships and patterns. BioEssays 2002;24:811-820.
10. Malinauskas T, Aricescu AR, Lu W et al. Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. Nat Struct Mol Biol 2011;18: 886-893.
11. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
12. Nusse R, van Ooyen A, Cox D et al. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984;307:131-136.
13. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787-1790.
14. Clements WM, Lowy AM, Groden J. Adenomatous polyposis coli/beta-catenin interaction and downstream targets: Altered gene expression in gastrointestinal tumors. Clin Colorectal Cancer 2003;3:113-120.
15. LiuW, Dong X, MaiMet al.Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating b-catenin/TCF signalling. Nat Genet 2000;26:146-147.
16. Salahshor S,Woodgett JR.Thelinksbetweenaxin and carcinogenesis. J Clin Pathol 2005;58:225-236.
17. Lee E, Salic A, Krüger R et al. The roles of APC and Axin derived from experimental and theoretical analysis of theWnt pathway. PLoS Biol 2003;1:E10.
18. Klarmann GJ, Decker A, Farrar WL. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 2008;3:59-63.
19. Matsuda Y, Schlange T, Oakeley EJ et al. WNT signaling enhances breast cancer cell motility and blockade of the WNTpathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 2009;11:R32.
20. Valencia A, Román-Gómez J, Cervera J et al. Wnt signaling pathway is epigenetically regulated by methylation ofWnt antagonists in acute myeloid leukemia. Leukemia 2009;23:1658-1666.
21. Minke KS, Staib P, Puetter A et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 2009;82:165-175.
22. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014.
23. Katoh M,Katoh M.WNTsignaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13:4042-4045.
24. Gurney A, Axelrod F, Bond CJ et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA 2012;109:11717-11722.
25. Smith DC, Rosen LS, Chugh R et al. First-inhuman evaluation of the human monoclonal antibody vantictumab (OMP-18r5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. J Clin Oncol 2013;31(suppl):2540a.
26. Jimeno A, Gordon M, Chugh R et al. A first-inhuman phase 1 study of anticancer stem cell agent OMP-54f28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors. J Clin Oncol 2014;32(suppl):2505a.
27. Blagodatski A, Poteryaev D, Katanaev VL. Targeting theWnt pathways for therapies. Mol Cell Ther 2014;2:28.
28. Jiang X, Hao HX, Growney JD et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2013;110:12649-12654.
29. GiannakisM, Hodis E, JasmineMu X et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 2014;46:1264-1266.
30. Pozzi S, Fulciniti M, Yan H et al. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 2013;53: 487-496.
31. Fulciniti M, Tassone P, Hideshima T et al. Anti- DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114: 371-379.
32. Munshi NC, Abonour R, Beck JT et al. Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: Results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression [abstract 331]. Presented at: ASH annual meeting; December 8-12, 2012; Atlanta, GA.
33. Lau T, Chan E, CallowMet al. A novel tankyrase small-molecule inhibitor suppresses APC mutationdriven colorectal tumor growth. Cancer Res 2013; 73:3132-3144.
34. Waaler J, Machon O, Tumova L et al. A novel tankyrase inhibitor decreases canonicalWnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutantmice. Cancer Res 2012;72:2822-2832.
35. Busch AM, Johnson KC, Stan RV et al. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer 2013;13:211.
36. El-Khoueiry AB, Ning Y, Yang D et al. A phase I first-in-humanstudyof PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol 2013;31(suppl): 2501a.
37. Cha JY, Jung J-E, Lee K-H et al. Anti-tumor activity of novel small molecule Wnt signaling inhibitor, CWP232291, in multiple myeloma [abstract 3038]. Presented at: ASH annual meeting; December 4-7, 2010; Orlando, FL.
38. Goodall J, Martinozzi S, Dexter TJ et al. Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol Cell Biol 2004;24:2915-2922.
39. Arozarena I, Bischof H, Gilby D et al. In melanoma, beta-catenin is a suppressor of invasion. Oncogene 2011;30:4531-4543.
40. MaelandsmoGM, HolmR, Nesland JMet al. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 2003;9: 3383-3388.
41. Damsky WE, Curley DP, Santhanakrishnan M et al. b-catenin signaling controls metastasis in Brafactivated Pten-deficient melanomas. Cancer Cell 2011;20:741-754.
42. Kageshita T, Hamby CV, Ishihara T et al. Loss of b-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 2001;145:210-216.
43. Grossmann AH,Yoo JH, Clancy J et al.The small GTPase ARF6 stimulates b-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal 2013;6:ra14.
44. WebsterMR,Weeraratna AT. AWnt-er migration: Theconfusingroleofb-catenininmelanomametastasis. Sci Signal 2013;6:pe11. doi:10.1126/scisignal.2004114
45. Zheng D, Decker KF, Zhou T et al. Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.Mol Cancer Res 2013;11:482-493.
46. Yu M,Ting DT, Stott SL et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487:510-513.
47. Lee GT, Kang DI, Ha YS et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer 2014;110:1634-1644.
48. Imbert A, Eelkema R, Jordan S et al. Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 2001;153:555-568.
49. Fre S,Pallavi SK,HuygheMet al. NotchandWnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci USA 2009;106:6309-6314.
50. Kwon C, Cheng P, King IN et al. Notch posttranslationally regulatesb-catenin protein in stem and progenitor cells. Nat Cell Biol 2011;13:1244-1251.
51. Pacheco-Pinedo EC, Durham AC, Stewart KM et al. Wnt/b-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest 2011;121:1935-1945.
52. Tenbaum SP, Ord óñez-Morán P, Puig I et al. b-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18:892-901.
53. Laird PW, Jackson-Grusby L, Fazeli A et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
54. Sansom OJ, Berger J, Bishop SM et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 2003;34:145-147.
55. Jiang X, Tan J, Li J et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008;13:529-541.
56. Mahmoudi T, Boj SF, Hatzis P et al. The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/ b-catenin coactivators essential for intestinal homeostasis. PLoS Biol 2010;8:e1000539.
57. Wu Y, Li J, Sun CY et al. Epigenetic inactivation of the canonical Wnt antagonist secreted frizzledrelated protein 1 in hepatocellular carcinoma cells. Neoplasma 2012;59:326-332.
58. Taniguchi H, Yamamoto H, Hirata T et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24:7946-7952.
59. Goeppert B, Konermann C, Schmidt CR et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology 2014;59:544-554.
60. Guo Y, GuoW, Chen Z et al. Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma. Neoplasma 2011;58:110-117.
61. Björklund P, Svedlund J, Olsson AK et al. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One 2009;4: e4243.
62. Moreno-Bueno G, Hardisson D, Sánchez C et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002; 21:7981-7990.
63. Delmas AL, Riggs BM, Pardo CE et al. WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis 2011;32:1625-1633.
64. Ford CE, Jary E,MaSS et al.TheWnt gatekeeper SFRP4 modulates EMT, cell migration and downstreamWnt signalling in serous ovarian cancer cells. PLoS One 2013;8:e54362.
65. Yee DS, Tang Y, Li X et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 2010;9:162.
66. Chow A, Amemiya Y, Sugar L et al. Wholetranscriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer. Anticancer Res 2012;32: 3629-3641.
67. Kim JT, Li J, Jang ER et al. Deregulation ofWnt/ b-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis 2013;34:953-961.
68. Trautmann M, Sievers E, Aretz S et al. SS18-SSX fusion protein-induced Wnt/b-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 2014;33:5006-5016.
69. Vijayakumar S, Liu G, Rus IA et al. Highfrequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/b-catenin target gene, CDC25A. Cancer Cell 2011;19:601-612.
70. Biechele TL, Kulikauskas RM, Toroni RA et al. Wnt/b-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 2012;5: ra3.
71. Mullighan CG, Zhang J, Kasper LH et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471:235-239.
72. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. [published correction appears in Proc Natl Acad Sci USA 2004;101:16707]. Proc Natl Acad Sci USA 2004;101:12682-12687.
73. Mazieres J, He B, You L et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64: 4717-4720.
74. Miyake Y,Matsushita H,Yamamoto K. Anti-60s ribosomal protein l29 antibody: New anticancer agent discovered from human sera. J Clin Oncol 2013;31(suppl):3071a.
75. Lepourcelet M, Chen YN, France DS et al. Small-molecule antagonists of the oncogenic Tcf/ beta-catenin protein complex. Cancer Cell 2004;5: 91-102.
76. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-107.
77. Brudvik KW, Paulsen JE, Aandahl EM et al. Protein kinase A antagonist inhibits b-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/1) mice. Mol Cancer 2011;10:149.
78. Huang SM, Mishina YM, Liu S et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-620.